TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04437264

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intermittent feed participant
Description: Patients will be assigned to receive intermittent enteral feeding protocol. They will receive four equal volume feeds at 8:00, 12:00, 16:00, and 20:00 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Continuous feeds participant
Description: Patients will be assigned to receive continuous enteral feeding protocol. Typical goal rates are in the range of 60 to 80 mL per hour for 24 hours per day.
Study: NCT01740362

Intervention type: DRUG
Group type: OTHER
Intervention: CP-690,550
Description: 10 mg (2 x 5 mg tablets), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10 mg (2 x 5 mg tablets), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10 mg (2 x 5 mg tablets), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10 mg (2 x 5 mg tablets), single dose
Study: NCT04702230

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Baseline and follow-up MRI at 1 and 3 months post-TAE or post-TARE

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Baseline and follow-up MRI at 1 and 3 months post-TAE or post-TARE
Study: NCT02599051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini-arc
Description: We will place a single incision sling at the time of surgery for stress urinary incontinence

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monarc
Description: We will place a transobturator sling at the time of surgery for stress urinary incontinence
Study: NCT01894412

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept (Enbrel)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept (Enbrel)
Study: NCT04663672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Vivo Exposure
Description: Participants will receive 40 minutes of in-vivo exposure therapy to feared targets in the presence of a distinctive exposure scent.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: In-Vivo Exposure
Description: Participants will receive 40 minutes of in-vivo exposure therapy to feared targets in the presence of a distinctive exposure scent.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: In-Vivo Exposure
Description: Participants will receive 40 minutes of in-vivo exposure therapy to feared targets in the presence of a distinctive exposure scent.
Study: NCT00990288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemostatic Matrix
Description: FloSeal will be administered following the cementing of all knee components. Prior to release of the tourniquet and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissues by the use of a delivery syringe, Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.
Study: NCT02315820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induction of labor group (Group I)
Description: Women at 38-40+3 weeks with estimated fetal weight 3800-4500 will be offered ripening and IOL.
Study: NCT01239680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Intravenous 25 grams once over 6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer's Lactate
Description: Intravenous 1 liter once over 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer's Lactate
Description: Intravenous 1 liter once over 6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Glutamine)
Description: Given Intravenously in 1 liter Lactated Ringer's
Study: NCT00729586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT01631188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Aortic Valve
Description: Patients having minimally invasive aortic valve surgery will have a pacing wire placed through the endovent catheter. The anesthesiologist will attempt to pace the ventricle with this wire if needed to wean from bypass.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Aortic Valve Surgery
Description: The Anesthesiologist will advance a pacing wire through the Endovent Catheter under TEE in order to pace the heart when the subject is coming off the Cardiopulmonary bypass machine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manipulation in OR surgical technique
Description: Endovent and pacing wire when coming off cardiopulmonary bypass
Study: NCT02190058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1971a
Description: suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching DS-1971a
Study: NCT01330927

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VA106483
Description: Once daily oral dose of placebo for 2 nights~Once daily oral dose of 0.5 mg VA106483 for 2 nights~Once daily oral dose of 1 mg VA106483 for 2 nights~Once daily oral dose of 2 mg VA106483 for 2 nights~Once daily oral dose of 4 mg VA106483 for 2 nights~Placebo: as above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483
Description: Once daily oral dose of placebo for 2 nights~Once daily oral dose of 0.5 mg VA106483 for 2 nights~Once daily oral dose of 1 mg VA106483 for 2 nights~Once daily oral dose of 2 mg VA106483 for 2 nights~Once daily oral dose of 4 mg VA106483 for 2 nights~Placebo: as above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483
Description: Once daily oral dose of placebo for 2 nights~Once daily oral dose of 0.5 mg VA106483 for 2 nights~Once daily oral dose of 1 mg VA106483 for 2 nights~Once daily oral dose of 2 mg VA106483 for 2 nights~Once daily oral dose of 4 mg VA106483 for 2 nights~Placebo: as above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483
Description: Once daily oral dose of placebo for 2 nights~Once daily oral dose of 0.5 mg VA106483 for 2 nights~Once daily oral dose of 1 mg VA106483 for 2 nights~Once daily oral dose of 2 mg VA106483 for 2 nights~Once daily oral dose of 4 mg VA106483 for 2 nights~Placebo: as above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483
Description: Once daily oral dose of placebo for 2 nights~Once daily oral dose of 0.5 mg VA106483 for 2 nights~Once daily oral dose of 1 mg VA106483 for 2 nights~Once daily oral dose of 2 mg VA106483 for 2 nights~Once daily oral dose of 4 mg VA106483 for 2 nights~Placebo: as above
Study: NCT02805491

Intervention type: OTHER
Intervention: meconium
Description: to evaluate internal exposure to pesticide

Intervention type: OTHER
Intervention: meconium
Description: to evaluate internal exposure to pesticide

Intervention type: OTHER
Intervention: self questionnaires to parents
Description: to evaluate external exposure to pesticide

Intervention type: OTHER
Intervention: self questionnaires to parents
Description: to evaluate external exposure to pesticide
Study: NCT03734341

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EZ START Titration
Description: The auto CPAP device gradually increases air pressure night-by-night until the preset therapeutic pressure is reached.~Pressure range: from 5 to 14 cmH2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication).~Titration pressure: fixed pressure that reduces rAHI below 10, mask leak below 10% of the session, time session above 4 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EZ START Titration
Description: The auto CPAP device gradually increases air pressure night-by-night until the preset therapeutic pressure is reached.~Pressure range: from 5 to 14 cmH2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication).~Titration pressure: fixed pressure that reduces rAHI below 10, mask leak below 10% of the session, time session above 4 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APAP Titration
Description: The auto CPAP device continuously adjusts the pressure in real time to the minimum pressure needed to maintain upper airway patency at any moment. Pressure range: 5 to 14 cm H2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication).~Titration pressure: visual analysis pressure that reduces rAHI below 10 during 90% of the session, mask leak below 10% of the session, therapeutic session above 4 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APAP Titration
Description: The auto CPAP device continuously adjusts the pressure in real time to the minimum pressure needed to maintain upper airway patency at any moment. Pressure range: 5 to 14 cm H2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication).~Titration pressure: visual analysis pressure that reduces rAHI below 10 during 90% of the session, mask leak below 10% of the session, therapeutic session above 4 hours.
Study: NCT00668239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreous triamcinolone
Description: Intravenous injection of 0.1 ml (4 mg) of triamcinolone acetate was performed through the pars plana in a surgical environment. The medication used was manipulated by the Ophthalmos chemist. This type of formulation is different from the similar American one (Kenalog ®) since it does not use a conservation agent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser therapy
Description: pan fotocoaglulation by laser therapy
Study: NCT00974870

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: needling treatment
Description: Needling treatment applied to half of the face at each study visit
Study: NCT01318434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB-1010 25mg BID
Description: capsule once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI Active
Description: Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB-1010 50mg BID
Description: Experimental Active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT00867932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: 5 mg/mL solution in 5% Dextrose
Study: NCT01894412

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HD203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HD203
Study: NCT03492840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RZL-012
Description: The dosing regimen will be a single dose treatment injection of RZL-012 in multiple sites

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RZL-012
Description: The dosing regimen will be a single dose treatment injection of RZL-012 in multiple sites
Study: NCT02691598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion
Description: Dexmedetomidine Hydrochloride or normal saline 4ug/ml；0.05ml/kg.h infusion for 24hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Infusion
Description: Dexmedetomidine Hydrochloride or normal saline 4ug/ml；0.05ml/kg.h infusion for 24hours
Study: NCT02844686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac SPECT
Description: 3-D dynamic acquisition of cardiac SPECT at rest and after pharmacological stress
Study: NCT03032770

Intervention type: DEVICE
Intervention: two-dimensional ultrasound and color Doppler
Description: the eligible participants will be searched for signs suggestive of placenta accreta; low implantation of the gestational sac (\<4cm from the external os), presence of placental lakes, Disruption of placental-myometrial interface and trophoblast overlapping a uterine scar by 2 dimensional transvaginal ultrasound and Intraplacental dilated vessels, turbulent blood flows and greatly increased periplacental vascularity by Doppler ultrasound by level II sonographer and co-investigator under his supervision using ultrasound device.

Intervention type: DEVICE
Intervention: two-dimensional ultrasound and color Doppler
Description: the eligible participants will be searched for signs suggestive of placenta accreta; low implantation of the gestational sac (\<4cm from the external os), presence of placental lakes, Disruption of placental-myometrial interface and trophoblast overlapping a uterine scar by 2 dimensional transvaginal ultrasound and Intraplacental dilated vessels, turbulent blood flows and greatly increased periplacental vascularity by Doppler ultrasound by level II sonographer and co-investigator under his supervision using ultrasound device.
Study: NCT03110939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperthermic perfusion
Description: hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after surgery of advanced lung cancer/esophageal cancer)
Study: NCT03375073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive communication during medical transmission
Description: Use of positive communication for medical transmission to the anaesthetic team who takes over the patient.
Study: NCT04485065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI188+azacitidine
Description: Escalating and maintenance dose of IBI188 will be administered 30mg/kg, IV(intravenous infusion),Q4W~Drug:Azacitidine Azacitidine will be administered daily for 7 days, IH, Q4W
Study: NCT01221844

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lattoglobina (Grunenthal) containing bLf
Description: One capsule of Lattoglobina contains 100 mg of bLf. Dosage: one capsule twice a day before meals. In twin pregnancy or in severe anemia the dosage is increased to 2 capsules twice a day before meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FerroGrad by Abbott
Description: Dosage: one tablet/day containing 540 mg of ferrous sulfate during meals
Study: NCT00873470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophagal stimulation
Description: ECG (rest) esophagal stimulation (rest and during effort)
Study: NCT01887743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: This will be a single dose study where participants will receive 1.2mg/kg or no more than 100mg total one time dose as a liquid containing Carbon 13 labeled Pantoprazole with a final concentration of 4.0mg/mL.
Study: NCT00081861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: 10 mg/kg given intravenously every 2 weeks for 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 given intravenously weekly for 8 doses, 30 minutes to 1 hour following Bevacizumab.
Study: NCT02760043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8mg (2mL) of Dexamethasone added to standard LIA mixture

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 0.9% NaCl Placebo
Description: 2mL of 0.9% NaCl placebo (saline) added to standard LIA mixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIA Combination Mixture
Description: 150mL 2% Ropivacaine, 30mg Ketorolac and 0.6mg of Epinephrine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: LIA Combination Mixture
Description: 150mL 2% Ropivacaine, 30mg Ketorolac and 0.6mg of Epinephrine
Study: NCT03183037

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Acupuncture
Description: Subjects in this group will receive the sham acupuncture procedure on the same schedule as subjects in the real acupuncture group. In both groups, patients' eyes will be covered with patches so they cannot observe the treatment procedure. To improve incentive to join and stay in the study, we will unblind all patients at Week 12, and offer those randomized to the Sham group 8 weeks of Acu (real) treatment. All points used will be documented.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: Patients go to clinic three times during the study, at Baseline, Week 8, and Week 12 to undergo QST and CPM tests. Patients will complete all questionnaires (CIPN severity by 0-10 11-point numeric rating scale, FACT/GOG-Ntx-11, NPS) and their pain medication use at these time points. Week 4 questionnaires can be completed over the phone. As an incentive for patients to join the study - and for those randomized to control to stay in the study - controls will be offered 8 weeks of Acu (real) treatment once they have completed Week 12 assessments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: FACT/GOG-Ntx, Neuropathic Pain Scale (NPS),Treatment Expectancy Scale (TES), Quantitative Sensory Testing (QST), Insomnia Severity Index (ISI), Hospital Anxiety and Depression Scale (HADS), Brief Fatigue Inventory (BFI)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: questionnaires
Description: FACT/GOG-Ntx, Neuropathic Pain Scale (NPS),Treatment Expectancy Scale (TES), Quantitative Sensory Testing (QST), Insomnia Severity Index (ISI), Hospital Anxiety and Depression Scale (HADS), Brief Fatigue Inventory (BFI)
Study: NCT01539200

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ONS+JDR
Description: Oral Nutritional Supplement with Jacques-Delacroze Eurythmic training

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: JDR
Description: Jacques-Delacroze Eurythmic training with placebo ONS
Study: NCT00129298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiagabine
Description: The tiagabine group will start receiving tiagabine 4mg in the evening of the first day on week 2. The dose will be titrated every third day, until the target dose of 32mg/day is achieved by week 5. The study medication must be titrated to 32 mg/day or to the subject's maximum tolerated dose (MTD).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiagabine
Description: The tiagabine group will start receiving tiagabine 4mg in the evening of the first day on week 2. The dose will be titrated every third day, until the target dose of 32mg/day is achieved by week 5. The study medication must be titrated to 32 mg/day or to the subject's maximum tolerated dose (MTD).
Study: NCT03183037

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: questionnaires
Description: FACT/GOG-Ntx, Neuropathic Pain Scale (NPS),Treatment Expectancy Scale (TES), Quantitative Sensory Testing (QST), Insomnia Severity Index (ISI), Hospital Anxiety and Depression Scale (HADS), Brief Fatigue Inventory (BFI)
Study: NCT03019367

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical cord milking UCM
Description: At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. This procedure infuses a placental transfusion of blood into the preterm neonate and can be done in 15-20 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cord clamping DCC
Description: At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.
Study: NCT01862627

Intervention type: PROCEDURE
Intervention: Optical coherence tomography
Study: NCT03521765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cancer education
Description: Those participants in the OT intervention group were given a consultation based on a CRC education handbook by an occupational therapist for discharge preparation (about 30 minutes) and after each follow-up visit to the clinic (about 15-20 minutes); the non-intervention group participants were given a CRC education handbook (the same handbook) only for discharge preparation. For the first OT consultation, in the first 15 minutes, the occupational therapist educated the participants based on the CRC education handbook chapter by chapter. The next 15 minutes, the occupational therapist interacted with the participants and provided them customized lifestyle suggestions. For the each following (second and third) consultations, occupational therapists interacted with the participants and provided customized suggestions based on the participants' lifestyle at home.
Study: NCT05034757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HA only
Description: HA injection only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESWT once
Description: ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESWT twice
Description: ESWT of the shoulder the patient will receives STORZ Extracorporeal Shock Wave Therapy 3000 impulses (each point) of shockwaves at 24kV (energy flux density, 0.32mJ/mm2) to the affected shoulder
Study: NCT01688934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V116517 50-mg tablets
Description: Taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V116517 30-mg tablets
Description: Taken orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen 500-mg capsules
Description: Taken orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily
Study: NCT02169115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: 150mg, s.c., every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: 300mg, s.c., every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, s.c., every 4 weeks
Study: NCT00530725

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chest drainage
Description: may be a chest tube of chest drainage procedure of any type (ie formal tube, pig-tail catheter, etc)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: close clinical observation
Description: close clinical observation in an operating room or intensive care unit without active intervention
Study: NCT05029297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin